Basic and clinical examinations of latamoxef in neonates and immature infants

Masahiro Tojo, Keisuke Sunakawa, Seiichiro Nanri, Hironobu Akita, Satoshi Iwata, Yukio Iwasaki, Takefumi Kanemtisu, Yoshitake Satoh, Tadao Oikawa, Mitsuru Osano, Yasuo Ichihashi, Kazuo Ishikawa, Kensuke Shirane, Makoto Hirose, Hiroyuki Tsuchiya, Yutaka Taguchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Latamoxef (LMOX) was used in the treatment and prophylaxis of infections in neonates and immature infants. The following results were obtained. 1. Mean serum concentrations (bioassay) 30 minutes after a single intravenous injection of about 20 mg/kg of LMOX were 49.9mcg/ml in neonates and 47.3mcg/ml in immature infants aged 0-3 days, 54.1 mcg/ml in neonates and 60.6mcg/ml in immature infants aged 4~7 days, 48.9mcg/ml in neonates and 46.7 mcg/ml in immature infants aged 8-28 days and 62.1 mcg/ml in immature infants aged over 29 days. Six-hour values were 24.1 mcg/ml, 22.5 mcg/ml, 15.9 mcg/ml, 27.2 mcg/ml, 12.9 mcg/ml, 19.1 mcg/ml and 12.8 mcg/ml, respectively. 2. Mean serum concentration half-lives were 6.70 hotirs in neonates and 8.16 hours in immature infants ggcH 0-3 days, 3.68 hours in neonates and 5.83 hours in immature infants aged 4-7 days, 3.06 hours in neonates and 4.47 hours in immature infants aged 8-28 days and 2.59 hours in immature infants aged over 29 days. 3. Adequate Hiniral efficacy can be expected by the intravenous injection of LMOX in doses of 20 mg/kg 1-2 times daily, in neonates and immature infants aged 0�3 days, 20 mg/kg 2�3 times daily, in neonates and immature infants aged 4-7 days and 20 mg/kg 3 times daily, in neonates and immature infants aged 8-28 4. The clinical efficacy of LMOX was good in 5 cases of sepsis (including suspected cases), 5 cases of urinary tract infection, 2 cases of respitary tract infection and 6 cases of intrauterine urfection (including suspected cases). Oiily a case of respiratory tract infections due to P. aeruginosa was thought to be ineffective. 5. Bleeding tendency was noted in 3 cases, which results from secondary vitamin K deficiency should be checked carefully during the administration of LMOX.

Original languageEnglish
Pages (from-to)2312-2321
Number of pages10
JournalThe Japanese Journal of Antibiotics
Volume36
Issue number9
DOIs
Publication statusPublished - 1983

Fingerprint

Moxalactam
Newborn Infant
Intravenous Injections
Vitamin K Deficiency
Infection
Serum
Urinary Tract Infections
Respiratory Tract Infections
Biological Assay

ASJC Scopus subject areas

  • Medicine(all)
  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Tojo, M., Sunakawa, K., Nanri, S., Akita, H., Iwata, S., Iwasaki, Y., ... Taguchi, Y. (1983). Basic and clinical examinations of latamoxef in neonates and immature infants. The Japanese Journal of Antibiotics, 36(9), 2312-2321. https://doi.org/10.11553/antibiotics1968b.36.2312

Basic and clinical examinations of latamoxef in neonates and immature infants. / Tojo, Masahiro; Sunakawa, Keisuke; Nanri, Seiichiro; Akita, Hironobu; Iwata, Satoshi; Iwasaki, Yukio; Kanemtisu, Takefumi; Satoh, Yoshitake; Oikawa, Tadao; Osano, Mitsuru; Ichihashi, Yasuo; Ishikawa, Kazuo; Shirane, Kensuke; Hirose, Makoto; Tsuchiya, Hiroyuki; Taguchi, Yutaka.

In: The Japanese Journal of Antibiotics, Vol. 36, No. 9, 1983, p. 2312-2321.

Research output: Contribution to journalArticle

Tojo, M, Sunakawa, K, Nanri, S, Akita, H, Iwata, S, Iwasaki, Y, Kanemtisu, T, Satoh, Y, Oikawa, T, Osano, M, Ichihashi, Y, Ishikawa, K, Shirane, K, Hirose, M, Tsuchiya, H & Taguchi, Y 1983, 'Basic and clinical examinations of latamoxef in neonates and immature infants', The Japanese Journal of Antibiotics, vol. 36, no. 9, pp. 2312-2321. https://doi.org/10.11553/antibiotics1968b.36.2312
Tojo, Masahiro ; Sunakawa, Keisuke ; Nanri, Seiichiro ; Akita, Hironobu ; Iwata, Satoshi ; Iwasaki, Yukio ; Kanemtisu, Takefumi ; Satoh, Yoshitake ; Oikawa, Tadao ; Osano, Mitsuru ; Ichihashi, Yasuo ; Ishikawa, Kazuo ; Shirane, Kensuke ; Hirose, Makoto ; Tsuchiya, Hiroyuki ; Taguchi, Yutaka. / Basic and clinical examinations of latamoxef in neonates and immature infants. In: The Japanese Journal of Antibiotics. 1983 ; Vol. 36, No. 9. pp. 2312-2321.
@article{d36a61dba36542b8a2839b10653499f9,
title = "Basic and clinical examinations of latamoxef in neonates and immature infants",
abstract = "Latamoxef (LMOX) was used in the treatment and prophylaxis of infections in neonates and immature infants. The following results were obtained. 1. Mean serum concentrations (bioassay) 30 minutes after a single intravenous injection of about 20 mg/kg of LMOX were 49.9mcg/ml in neonates and 47.3mcg/ml in immature infants aged 0-3 days, 54.1 mcg/ml in neonates and 60.6mcg/ml in immature infants aged 4~7 days, 48.9mcg/ml in neonates and 46.7 mcg/ml in immature infants aged 8-28 days and 62.1 mcg/ml in immature infants aged over 29 days. Six-hour values were 24.1 mcg/ml, 22.5 mcg/ml, 15.9 mcg/ml, 27.2 mcg/ml, 12.9 mcg/ml, 19.1 mcg/ml and 12.8 mcg/ml, respectively. 2. Mean serum concentration half-lives were 6.70 hotirs in neonates and 8.16 hours in immature infants ggcH 0-3 days, 3.68 hours in neonates and 5.83 hours in immature infants aged 4-7 days, 3.06 hours in neonates and 4.47 hours in immature infants aged 8-28 days and 2.59 hours in immature infants aged over 29 days. 3. Adequate Hiniral efficacy can be expected by the intravenous injection of LMOX in doses of 20 mg/kg 1-2 times daily, in neonates and immature infants aged 0�3 days, 20 mg/kg 2�3 times daily, in neonates and immature infants aged 4-7 days and 20 mg/kg 3 times daily, in neonates and immature infants aged 8-28 4. The clinical efficacy of LMOX was good in 5 cases of sepsis (including suspected cases), 5 cases of urinary tract infection, 2 cases of respitary tract infection and 6 cases of intrauterine urfection (including suspected cases). Oiily a case of respiratory tract infections due to P. aeruginosa was thought to be ineffective. 5. Bleeding tendency was noted in 3 cases, which results from secondary vitamin K deficiency should be checked carefully during the administration of LMOX.",
author = "Masahiro Tojo and Keisuke Sunakawa and Seiichiro Nanri and Hironobu Akita and Satoshi Iwata and Yukio Iwasaki and Takefumi Kanemtisu and Yoshitake Satoh and Tadao Oikawa and Mitsuru Osano and Yasuo Ichihashi and Kazuo Ishikawa and Kensuke Shirane and Makoto Hirose and Hiroyuki Tsuchiya and Yutaka Taguchi",
year = "1983",
doi = "10.11553/antibiotics1968b.36.2312",
language = "English",
volume = "36",
pages = "2312--2321",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "9",

}

TY - JOUR

T1 - Basic and clinical examinations of latamoxef in neonates and immature infants

AU - Tojo, Masahiro

AU - Sunakawa, Keisuke

AU - Nanri, Seiichiro

AU - Akita, Hironobu

AU - Iwata, Satoshi

AU - Iwasaki, Yukio

AU - Kanemtisu, Takefumi

AU - Satoh, Yoshitake

AU - Oikawa, Tadao

AU - Osano, Mitsuru

AU - Ichihashi, Yasuo

AU - Ishikawa, Kazuo

AU - Shirane, Kensuke

AU - Hirose, Makoto

AU - Tsuchiya, Hiroyuki

AU - Taguchi, Yutaka

PY - 1983

Y1 - 1983

N2 - Latamoxef (LMOX) was used in the treatment and prophylaxis of infections in neonates and immature infants. The following results were obtained. 1. Mean serum concentrations (bioassay) 30 minutes after a single intravenous injection of about 20 mg/kg of LMOX were 49.9mcg/ml in neonates and 47.3mcg/ml in immature infants aged 0-3 days, 54.1 mcg/ml in neonates and 60.6mcg/ml in immature infants aged 4~7 days, 48.9mcg/ml in neonates and 46.7 mcg/ml in immature infants aged 8-28 days and 62.1 mcg/ml in immature infants aged over 29 days. Six-hour values were 24.1 mcg/ml, 22.5 mcg/ml, 15.9 mcg/ml, 27.2 mcg/ml, 12.9 mcg/ml, 19.1 mcg/ml and 12.8 mcg/ml, respectively. 2. Mean serum concentration half-lives were 6.70 hotirs in neonates and 8.16 hours in immature infants ggcH 0-3 days, 3.68 hours in neonates and 5.83 hours in immature infants aged 4-7 days, 3.06 hours in neonates and 4.47 hours in immature infants aged 8-28 days and 2.59 hours in immature infants aged over 29 days. 3. Adequate Hiniral efficacy can be expected by the intravenous injection of LMOX in doses of 20 mg/kg 1-2 times daily, in neonates and immature infants aged 0�3 days, 20 mg/kg 2�3 times daily, in neonates and immature infants aged 4-7 days and 20 mg/kg 3 times daily, in neonates and immature infants aged 8-28 4. The clinical efficacy of LMOX was good in 5 cases of sepsis (including suspected cases), 5 cases of urinary tract infection, 2 cases of respitary tract infection and 6 cases of intrauterine urfection (including suspected cases). Oiily a case of respiratory tract infections due to P. aeruginosa was thought to be ineffective. 5. Bleeding tendency was noted in 3 cases, which results from secondary vitamin K deficiency should be checked carefully during the administration of LMOX.

AB - Latamoxef (LMOX) was used in the treatment and prophylaxis of infections in neonates and immature infants. The following results were obtained. 1. Mean serum concentrations (bioassay) 30 minutes after a single intravenous injection of about 20 mg/kg of LMOX were 49.9mcg/ml in neonates and 47.3mcg/ml in immature infants aged 0-3 days, 54.1 mcg/ml in neonates and 60.6mcg/ml in immature infants aged 4~7 days, 48.9mcg/ml in neonates and 46.7 mcg/ml in immature infants aged 8-28 days and 62.1 mcg/ml in immature infants aged over 29 days. Six-hour values were 24.1 mcg/ml, 22.5 mcg/ml, 15.9 mcg/ml, 27.2 mcg/ml, 12.9 mcg/ml, 19.1 mcg/ml and 12.8 mcg/ml, respectively. 2. Mean serum concentration half-lives were 6.70 hotirs in neonates and 8.16 hours in immature infants ggcH 0-3 days, 3.68 hours in neonates and 5.83 hours in immature infants aged 4-7 days, 3.06 hours in neonates and 4.47 hours in immature infants aged 8-28 days and 2.59 hours in immature infants aged over 29 days. 3. Adequate Hiniral efficacy can be expected by the intravenous injection of LMOX in doses of 20 mg/kg 1-2 times daily, in neonates and immature infants aged 0�3 days, 20 mg/kg 2�3 times daily, in neonates and immature infants aged 4-7 days and 20 mg/kg 3 times daily, in neonates and immature infants aged 8-28 4. The clinical efficacy of LMOX was good in 5 cases of sepsis (including suspected cases), 5 cases of urinary tract infection, 2 cases of respitary tract infection and 6 cases of intrauterine urfection (including suspected cases). Oiily a case of respiratory tract infections due to P. aeruginosa was thought to be ineffective. 5. Bleeding tendency was noted in 3 cases, which results from secondary vitamin K deficiency should be checked carefully during the administration of LMOX.

UR - http://www.scopus.com/inward/record.url?scp=0021062286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021062286&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.36.2312

DO - 10.11553/antibiotics1968b.36.2312

M3 - Article

C2 - 6655850

AN - SCOPUS:0021062286

VL - 36

SP - 2312

EP - 2321

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 9

ER -